Which has preferable valuation & earnings, KLRA or EIKN?

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A Eikon Therapeutics N/A N/A N/A -$2.46 N/A

Is KLRA or EIKN more profitable?

Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Eikon Therapeutics N/A N/A N/A

Does the media refer more to KLRA or EIKN?

In the previous week, Kailera Therapeutics had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 4 mentions for Kailera Therapeutics and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Kailera Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, MBX or EIKN?

MBX Biosciences is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Eikon Therapeutics N/A N/A N/A -$2.46 N/A

Is MBX or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Eikon Therapeutics N/A N/A N/A

Does the media prefer MBX or EIKN?

In the previous week, MBX Biosciences had 1 more articles in the media than Eikon Therapeutics. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat MBX Biosciences' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation and earnings, TRVI or EIKN?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Eikon Therapeutics N/A N/A N/A -$2.46 N/A

Is TRVI or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Eikon Therapeutics N/A N/A N/A

Does the media favor EIKN or TARS?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Eikon Therapeutics. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Tarsus Pharmaceuticals' score of 0.02 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tarsus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NRIX or EIKN?

In the previous week, Nurix Therapeutics had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 5 mentions for Nurix Therapeutics and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Nurix Therapeutics' score of 0.41 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Eikon Therapeutics (EIKN) Competitors

$12.54 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$11.97 -0.57 (-4.58%)

As of 07/2/2026 07:50 PM Eastern

Compare

EIKN vs. KLRA, MBX, TRVI, TARS, and NRIX

Should you buy Eikon Therapeutics stock or one of its competitors? MarketBeat compares Eikon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eikon Therapeutics include Kailera Therapeutics (KLRA), MBX Biosciences (MBX), Trevi Therapeutics (TRVI), Tarsus Pharmaceuticals (TARS), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

How does Eikon Therapeutics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Eikon Therapeutics (NASDAQ:EIKN) are both manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Kailera Therapeutics had 3 more articles in the media than Eikon Therapeutics. MarketBeat recorded 4 mentions for Kailera Therapeutics and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Kailera Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Eikon Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

Kailera Therapeutics currently has a consensus target price of $42.75, suggesting a potential upside of 94.41%. Eikon Therapeutics has a consensus target price of $25.20, suggesting a potential upside of 100.96%. Given Eikon Therapeutics' higher possible upside, analysts plainly believe Eikon Therapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Eikon Therapeutics	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Eikon Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Eikon Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Eikon Therapeutics (NASDAQ:EIKN) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, MBX Biosciences had 1 more articles in the media than Eikon Therapeutics. MarketBeat recorded 2 mentions for MBX Biosciences and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat MBX Biosciences' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MBX Biosciences is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

Eikon Therapeutics' return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Eikon Therapeutics	N/A	N/A	N/A

MBX Biosciences currently has a consensus price target of $60.22, suggesting a potential upside of 4.19%. Eikon Therapeutics has a consensus price target of $25.20, suggesting a potential upside of 100.96%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

MBX Biosciences and Eikon Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Eikon Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Eikon Therapeutics (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Trevi Therapeutics presently has a consensus target price of $22.67, indicating a potential upside of 26.42%. Eikon Therapeutics has a consensus target price of $25.20, indicating a potential upside of 100.96%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Eikon Therapeutics	N/A	N/A	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Eikon Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 1 mentions for Eikon Therapeutics and 0 mentions for Trevi Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Trevi Therapeutics' score of 0.00 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Trevi Therapeutics	Neutral
Eikon Therapeutics	Very Positive

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

Summary

Trevi Therapeutics and Eikon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Tarsus Pharmaceuticals?

Eikon Therapeutics (NASDAQ:EIKN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eikon Therapeutics currently has a consensus target price of $25.20, suggesting a potential upside of 100.96%. Tarsus Pharmaceuticals has a consensus target price of $90.67, suggesting a potential upside of 38.55%. Given Eikon Therapeutics' higher possible upside, equities research analysts clearly believe Eikon Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Eikon Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Eikon Therapeutics' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

Eikon Therapeutics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
Tarsus Pharmaceuticals	$451.36M	6.24	-$66.42M	-$1.14	N/A

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Eikon Therapeutics. MarketBeat recorded 3 mentions for Tarsus Pharmaceuticals and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Tarsus Pharmaceuticals' score of 0.02 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Eikon Therapeutics and Tarsus Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Eikon Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Eikon Therapeutics (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Nurix Therapeutics currently has a consensus price target of $32.20, suggesting a potential upside of 34.28%. Eikon Therapeutics has a consensus price target of $25.20, suggesting a potential upside of 100.96%. Given Eikon Therapeutics' higher probable upside, analysts plainly believe Eikon Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Eikon Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	29.53	-$264.46M	-$3.16	N/A
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A

Eikon Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Eikon Therapeutics' return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Eikon Therapeutics	N/A	N/A	N/A

In the previous week, Nurix Therapeutics had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 5 mentions for Nurix Therapeutics and 1 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.86 beat Nurix Therapeutics' score of 0.41 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Eikon Therapeutics beats Nurix Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	Eikon Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$678.90M	$538.08M	$5.20B	$12.48B
Dividend Yield	N/A	N/A	16.10%	6.51%
P/E Ratio	-5.10	N/A	23.91	24.70
Price / Sales	N/A	388.95	166.94	99.06
Price / Cash	N/A	N/A	35.06	57.09
Price / Book	N/A	2.94	13.25	6.46
Net Income	N/A	-$81.71M	$113.80M	$337.01M
7 Day Performance	9.52%	7.17%	0.93%	1.69%
1 Month Performance	39.96%	21.82%	1.08%	3.81%
1 Year Performance	N/A	-72.26%	10.03%	23.90%

Eikon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN Eikon Therapeutics	2.3734 of 5 stars	$12.54 flat	$25.20 +101.0%	N/A	$678.90M	N/A	N/A	384
KLRA Kailera Therapeutics	3.6399 of 5 stars	$21.27 -1.8%	$42.75 +101.0%	N/A	$2.76B	N/A	N/A	145	News Coverage Gap Down
MBX MBX Biosciences	0.8211 of 5 stars	$56.75 +5.4%	$60.22 +6.1%	N/A	$2.69B	N/A	N/A	N/A	News Coverage Gap Down
TRVI Trevi Therapeutics	2.191 of 5 stars	$18.81 +1.0%	$22.90 +21.8%	+204.1%	$2.67B	N/A	N/A	20
TARS Tarsus Pharmaceuticals	2.89 of 5 stars	$61.48 +0.4%	$90.67 +47.5%	+59.3%	$2.62B	$535.08M	N/A	50	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eikon Therapeutics (EIKN) Competitors

EIKN vs. KLRA, MBX, TRVI, TARS, and NRIX

How does Eikon Therapeutics compare to Kailera Therapeutics?

Summary

How does Eikon Therapeutics compare to MBX Biosciences?

Summary

How does Eikon Therapeutics compare to Trevi Therapeutics?

Summary

How does Eikon Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Eikon Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eikon Therapeutics (EIKN) Competitors

EIKN vs. KLRA, MBX, TRVI, TARS, and NRIX

How does Eikon Therapeutics compare to Kailera Therapeutics?

Does the media refer more to KLRA or EIKN?

Which has preferable valuation & earnings, KLRA or EIKN?

Do analysts rate KLRA or EIKN?

Is KLRA or EIKN more profitable?

Summary

How does Eikon Therapeutics compare to MBX Biosciences?

Does the media prefer MBX or EIKN?

Which has preferable earnings & valuation, MBX or EIKN?

Is MBX or EIKN more profitable?

Do analysts prefer MBX or EIKN?

Summary

How does Eikon Therapeutics compare to Trevi Therapeutics?

Do analysts prefer TRVI or EIKN?

Is TRVI or EIKN more profitable?

Do institutionals and insiders believe in TRVI or EIKN?

Does the media favor TRVI or EIKN?

Which has better valuation and earnings, TRVI or EIKN?

Summary

How does Eikon Therapeutics compare to Tarsus Pharmaceuticals?

Do insiders & institutionals have more ownership in EIKN or TARS?

Do analysts rate EIKN or TARS?

Is EIKN or TARS more profitable?

Which has better earnings and valuation, EIKN or TARS?

Does the media favor EIKN or TARS?

Summary

How does Eikon Therapeutics compare to Nurix Therapeutics?

Do analysts recommend NRIX or EIKN?

Which has preferable earnings and valuation, NRIX or EIKN?

Is NRIX or EIKN more profitable?

Does the media prefer NRIX or EIKN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools